Barts Health NHS Trust, London, United Kingdom.
St. George's Healthcare NHS Foundation Trust, St. George's Hospital, London, United Kingdom.
J Am Coll Cardiol. 2018 Oct 23;72(17):1989-1999. doi: 10.1016/j.jacc.2018.07.089.
A large proportion of patients presenting with non-ST-segment elevation myocardial infarction (NSTEMI) present with multivessel disease (MVD). There is uncertainty in the role of complete coronary revascularization in this group of patients.
The aim of this study was to investigate the outcomes of complete revascularization compared with culprit vessel-only intervention in a large contemporary cohort of patients undergoing percutaneous coronary intervention (PCI) for NSTEMI.
The authors undertook an observational cohort study of 37,491 NSTEMI patients treated between 2005 and 2015 at the 8 heart attack centers in London. Clinical details were recorded at the time of the procedure into local databases using the British Cardiac Intervention Society (BCIS) PCI dataset. A total of 21,857 patients (58.3%) presented with NSTEMI and MVD. Primary outcome was all-cause mortality at a median follow-up of 4.1 years (interquartile range: 2.2 to 5.8 years).
A total of 11,737 (53.7%) patients underwent single-stage complete revascularization during PCI for NSTEMI, rates that significantly increased during the study period (p = 0.006). Those patients undergoing complete revascularization were older and more likely to be male, diabetic, have renal disease and a history of previous myocardial infarction/revascularization compared with the culprit-only revascularization group. Although crude, in-hospital major adverse cardiac event rates were similar (5.2% vs. 4.8%; p = 0.462) between the 2 groups. Kaplan-Meier analysis demonstrated significant differences in mortality rates between the 2 groups (22.5% complete revascularization vs. 25.9% culprit vessel intervention; p = 0.0005) during the follow-up period. After multivariate Cox analysis (hazard ratio: 0.90; 95% confidence interval: 0.85 to 0.97) and the use of propensity matching (hazard ratio: 0.89; 95% confidence interval: 0.76 to 0.98) complete revascularization was associated with reduced mortality.
In NSTEMI patients with MVD, despite higher initial (in-hospital) mortality rates, single-stage complete coronary revascularization appears to be superior to culprit-only vessel PCI in terms of long-term mortality rates. This supports the need for further randomized study to confirm these findings.
很大一部分非 ST 段抬高型心肌梗死(NSTEMI)患者存在多血管病变(MVD)。对于这组患者,完全血运重建的作用尚不确定。
本研究旨在调查在接受经皮冠状动脉介入治疗(PCI)的 NSTEMI 大当代队列中,完全血运重建与罪犯血管仅干预相比的结局。
作者对 2005 年至 2015 年在伦敦 8 个心脏病发作中心接受治疗的 37491 例 NSTEMI 患者进行了观察性队列研究。临床细节在程序时使用英国心脏介入学会(BCIS)PCI 数据集记录到本地数据库中。共有 21857 例(58.3%)患者出现 NSTEMI 和 MVD。主要结局是中位随访 4.1 年(四分位距:2.2 至 5.8 年)时的全因死亡率。
共有 11737 例(53.7%)NSTEMI 患者在 PCI 期间进行了单阶段完全血运重建,在研究期间该比例显著增加(p=0.006)。与罪犯血管仅血运重建组相比,接受完全血运重建的患者年龄较大,更可能为男性、糖尿病、患有肾脏疾病和既往心肌梗死/血运重建史。尽管是粗略的,但两组患者住院期间主要不良心脏事件发生率相似(5.2% vs. 4.8%;p=0.462)。Kaplan-Meier 分析显示两组之间死亡率存在显著差异(22.5%完全血运重建 vs. 25.9%罪犯血管介入;p=0.0005)。多变量 Cox 分析(危险比:0.90;95%置信区间:0.85 至 0.97)和倾向匹配后(危险比:0.89;95%置信区间:0.76 至 0.98)均显示,完全血运重建与死亡率降低相关。
在存在 MVD 的 NSTEMI 患者中,尽管初始(住院期间)死亡率较高,但单阶段完全冠状动脉血运重建在长期死亡率方面似乎优于罪犯血管仅 PCI。这支持需要进一步的随机研究来证实这些发现。